Laddar...
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
The development of CDK 4/6 inhibitors has dramatically changed the therapeutic management of hormone receptor-positive (HR+) and HER2 negative metastatic breast cancer (MBC). In combination with fulvestrant, palbociclib, ribociclib and abemaciclib have each been approved for HR+/HER2- MBC following...
Sparad:
| I publikationen: | Breast Cancer (Dove Med Press) |
|---|---|
| Huvudupphovsmän: | , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7090187/ https://ncbi.nlm.nih.gov/pubmed/32256106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S196240 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|